Matthew W. Harding

Biochemistry, Genetics and Molecular Biology · Life Sciences

31h-index9.3kcitations66works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Signaling Pathways in Disease(26), Peptidase Inhibition and Analysis(12), Toxin Mechanisms and Immunotoxins(10), Drug Transport and Resistance Mechanisms(7), Immune Response and Inflammation(5)

Publications66 total

846 DISCOVERY OF A NEW SERIES OF POTENT, MULTI-GENOTYPE HCV NS5B INHIBITORS: IN VITRO ACTIVITY AND PRE-CLINICAL PHARMACOKINETIC RESULTS
Journal of Hepatology·2012
A Phase I Dose‐Ranging Study of the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of AVN944, an IMPDH Inhibitor, in Healthy Male Volunteers
The Journal of Clinical Pharmacology·2008· 15 cited
Efficacy of MK-0457 (VX-680) in combination with docetaxel in a p53 shRNA/vector dual flank NSCLC xenograft model
Molecular Cancer Therapeutics·2007
336 POSTER The aurora kinase inhibitor MK-0457 (VX-680) demonstrates anticancer activity alone or in combination with docetaxel (Dtx)
European Journal of Cancer Supplements·2007· 1 cited
Activity of the aurora kinase inhibitor MK-0457 (VX-680) in combination with taxotere
Journal of Clinical Oncology·2007· 3 cited
A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX‐710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer
Cancer·2007· 88 citedOpen Access
Synergistic Activity of the Aurora Kinase Inhibitor MK-0457 (VX-680) with Idarubicin, Ara-C, and Inhibitors of BCR-ABL.
Blood·2006· 10 cited
The Aurora Kinase Inhibitor VX-680 Induces Endoreduplication and Apoptosis Preferentially in Cells with Compromised p53-Dependent Postmitotic Checkpoint Function
Cancer Research·2006· 177 citedOpen Access
A phase II study of the safety and efficacy of the MDR inhibitor VX-710 combined with doxorubicin and vincristine in small cell lung cancer
Journal of Clinical Oncology·2006
Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy.
PubMed·2003· 56 cited
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer
Cancer Chemotherapy and Pharmacology·2003· 32 cited
A Phase II Study of the MDR Inhibitor Biricodar (INCEL, VX-710) and Paclitaxel in Women with Advanced Ovarian Cancer Refractory to Paclitaxel Therapy
Gynecologic Oncology·2002· 98 cited
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
PubMed·2002· 84 cited
Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
PubMed·2002· 60 cited
ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs
Expert Opinion on Investigational Drugs·2001· 87 cited
Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin
Journal of Clinical Oncology·2001· 106 cited
VX-497: A novel, selective IMPDH inhibitor and immunosuppressive agent
Journal of Pharmaceutical Sciences·2001· 3 cited
VX-497: A novel, selective IMPDH inhibitor and immunosuppressive agent
Journal of Pharmaceutical Sciences·2001· 64 cited
A Phase II study of IncelTM (biricodar, VX-710) in combination with paclitaxel in women with advanced breast cancer refractory to paclitaxel
European Journal of Cancer·1999
A Phase II study of the safety, pharmacokinetics and efficacy of IncelTM (biricodar, VX-710) in combination with mitoxantrone (M) and prednisone (P) in advanced hormone refractory prostate cancer (HRPC)
European Journal of Cancer·1999· 1 cited
page 1 of 4Next →

Frequent Co-authors

Robert E. Handschumacher(13), David J. Livingston(7), George Ku(5), Ene Ette(4), Keisuke Kuida(3), Mark Fleming(3), Giamila Fantuzzi(3), Ursula A. Germann(3), Varun Garg(3), Ian M. Armitage(3), Tsu‐Ju Yang(3), David W. Speicher(2), Judith A. Lippke(2), Michael Su(2), Richard A. Flavell(2), Andrzej Gałat(2), Adrian Puren(2), Charles A. Dinarello(2), Roland M. Wenger(2), Pravin Chaturvedi(2)